<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Joseph L. Goldstein</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Texas Southwestern Medical Center</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-8294-065X" target="_blank">0000-0002-8294-065X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Cardiovascular Disease, Familial Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>LDL Receptor, Cholesterol Metabolism, Statins</td>
</tr>
</table>
Joseph L. Goldstein
Overview
Joseph L. Goldstein is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Texas Southwestern Medical Center. Their research focuses on LDL Receptor, Cholesterol Metabolism, Statins, with particular emphasis on Cardiovascular Disease and Familial Hypercholesterolemia. With an h-index of 200, Goldstein is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Joseph L. Goldstein</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Texas Southwestern Medical Center</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-8294-065X" target="_blank">0000-0002-8294-065X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Cardiovascular Disease, Familial Hypercholesterolemia</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>LDL Receptor, Cholesterol Metabolism, Statins</td>
</tr>
</table>
Joseph L. Goldstein
Overview
Joseph L. Goldstein is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Texas Southwestern Medical Center. Their research focuses on LDL Receptor, Cholesterol Metabolism, Statins, with particular emphasis on Cardiovascular Disease and Familial Hypercholesterolemia. With an h-index of 200, Goldstein is among the most cited researchers in the neuroscience field[@orcid2026].
Goldstein's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Cardiovascular Disease and Familial Hypercholesterolemia. Their research group has made significant contributions to the fields of LDL Receptor, Cholesterol Metabolism, Statins, publishing in high-impact journals including Cell.
Based at University of Texas Southwestern Medical Center, Goldstein collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- Cardiovascular Disease
- Familial Hypercholesterolemia
Mechanisms of Interest
- LDL Receptor
- Cholesterol Metabolism
- Statins
Programmatic Emphasis
Goldstein's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Cardiovascular Disease and Familial Hypercholesterolemia. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the LDL Receptor, Cholesterol Metabolism, Statins domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[A receptor-mediated pathway for clearance of LDL](https://doi.org/10.1016/0092-8674(84)90347-1). Cell, 1984.[@receptormediated1984]
Recent Research
Recent PubMed-indexed publications (2024-present):
[The effect of acute psychologic and physiologic stress on tactile bougie use: a cadaveric airway study.](https://pubmed.ncbi.nlm.nih.gov/41721189/). CJEM. 2026.
[Let's Talk Tech: The Role of Technology in Neurology Education.](https://pubmed.ncbi.nlm.nih.gov/41720469/). Seminars in neurology. 2026.
[Deleterious consequences of Shiga toxin in the CNS.](https://pubmed.ncbi.nlm.nih.gov/41489386/). Microbiology and molecular biology reviews : MMBR. 2026.
[Feasibility and potential effects of mental imagery training on subjective cognitive function and brain connectivity in people with Parkinson's disease: A randomized pilot trial.](https://pubmed.ncbi.nlm.nih.gov/41482867/). Neuropsychological rehabilitation. 2026.
Collaborators and Research Network
[Michael S. Brown](/researchers/michael-brown)
Institutional Context
Primary institutional links: [University of Texas Southwestern Medical Center](/institutions/university-of-texas-southwestern-medical-center). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can LDL Receptor, Cholesterol Metabolism, Statins signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Cardiovascular Disease and Familial Hypercholesterolemia into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0002-8294-065X](https://orcid.org/0000-0002-8294-065X)
- Google Scholar: [Search for Joseph L. Goldstein](https://scholar.google.com/scholar?q=author%3A%22Joseph+L.+Goldstein%22)
- PubMed: [Author search for Joseph L. Goldstein](https://pubmed.ncbi.nlm.nih.gov/?term=Joseph+L.+Goldstein%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, A receptor-mediated pathway for clearance of LDL (1984)](https://doi.org/10.1016/0092-8674(84)
Unknown, ORCID profile for Joseph L. Goldstein (2026)